Search | Clinical Trials Finder

Conditions: Multiple Sclerosis
Interventions: Androgel 10 grams of gel containing 100 mg of testosterone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Severe Postpartum Depression
Interventions: BRII-296, Depo Medrol; Drug
Lead sponsor: Brii Biosciences Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 11
States / cities: Sherman Oaks, California • Torrance, California • Boynton Beach, Florida + 7 more

Conditions: Hemophagocytic Lymphohistiocytosis
Interventions: ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more

Conditions: Sepsis, Severe, Septic Shock
Interventions: Ascorbic Acid, Thiamine, Hydrocortisone, Sodium Chloride 0.9%; Drug
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lakewood, New Jersey • Toms River, New Jersey

Conditions: Breast Cancer
Interventions: fulvestrant, sorafenib tosylate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Venetoclax, Bortezomib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 14
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 2 more

Conditions: Prostatic Neoplasms
Interventions: Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab SAR650984, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Scottsdale, Arizona • Duarte, California • New Haven, Connecticut + 9 more

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Blepharitis
Interventions: Tobradex ST, Azasite; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Osteoporosis, Osteopenia
Interventions: Alendronate, Calcium Citrate, Vitamin D; Drug · Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 59 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions: PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer; Procedure · Radiation · Other + 1 more
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more

Conditions: Eclampsia
Interventions: Dexamethasone; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Lymphoma
Interventions: cisplatin, cyclophosphamide, cytarabine, dexamethasone, etoposide, autologous bone marrow transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: St. Luke's Medical Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1990
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hematologic Neoplasms
Interventions: Stem cell transplantation, Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Prednisone, Methotrexate, Cyclosporine, Apheresis; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 60
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Exudative Age-Related Macular Degeneration
Interventions: ranibizumab and dexamethasone, Ranibizumab; Drug
Lead sponsor: Subhransu K. Ray, M.D., Ph.D.; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Relapsed/Refractory, Multiple Myeloma
Interventions: Mezagitamab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Duarte, California • St Louis, Missouri • New York, New York + 3 more

Conditions: Prolonged QT Interval in EKG and Sudden Death
Interventions: Progesterone, Placebo, Ibutilide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD)
Interventions: Betamethasone; Drug
Lead sponsor: Khang Nguyen; Other
Eligibility: Up to 28 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Rotator Cuff Tear
Interventions: Oxandrolone, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Testosterone Treatment for Multiple Sclerosis

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Texture Analysis for Postmenopausal Osteoporosis

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?

Oxandrolone Rotator Cuff Trial